Advanced Search

 

Study ID Status Title Patient Level Data
SLGB4014 Completed Placebo controlled study during one year comparing the addition of salmeterol with an increase of the dose of the inhaled corticosteroid in asthmatic children already on treatment with inhaled corticosteroids.
SLGB4015 Completed One year treatment with either inhaled corticosteroid or a long acting beta-2-agonist in asthmatic children.
SLGF53 Completed A Multi-Centre, Double-Blind, Parallel Group Study to Evaluate the Efficacy of SEREVENT 50mg BID Versus Placebo BID all Administered via the Multi Dose Powder Inhaler (DISKUS/ACCUHALER) in Terms of Symptoms in the Treatment of Patients With Chronic Obstructive Pulmonary Disease
SLGF55 Completed Long-Term Treatment of Chronic Obstructive Pulmonary Disease with Salmeterol and the Additive Effect of Ipratropium. Extensive searching has revealed that no clinical study report is available for this study.
SLGF75 Completed (Inhaled Fluticasone propionate and Salmeterol in sputum induced study in asthma)Salmeterol plus low-dose fluticasone propionate (FP) versus high-dose fluticasone propionate (FP) in naive patients with mild to moderate asthma: effects on pulmonary function, and inflammatory markers of induced sputum
SLGH01 Completed The Determination of the Dose-Response Characteristics of Single Inhaled Doses (50mcg, 100mcg, and 200mcg) of GR33343G in Patients With Reversible Airways Obstruction
SLGH03 Completed The Determination of the Relative Potency of Inhaled GR33343G Metered-Dose Inhaler and GR33343G Dry Powder: A Cumulative Dose-Response Study in Patients With Reversible Airways Disease
SLGH04 Completed The Determination of the Dose-Response Characteristics of Single Inhaled Doses (12.5mcg, 25mcg, 50mcg, and 100mcg) of GR33343G in Patients With Asthma. A Randomised, Double-Blind Comparison With Inhaled Salbutamol.
SLGH05 Completed The Determination of the Dose-Response Characteristics of Single Inhaled Doses of GR33343G (12.5mcg, 25mcg, 50mcg, and 100mcg) Administered as a Dry Powder. A Comparison With Salbutamol (200mcg) Administered From a Metered-Dose Inhaler.
SLGH06 Completed A Single-Centre, Double-Blind, Within-Patient Study to Determine the Dose-Response Characteristics of GR33343G (12.5mcg-100mcg) Given by Metered-Dose Inhaler in Patients With Asthma. A Comparison With Salbutamol (200mcg) Given by Metered-Dose Inhaler.
SLGH07 Completed To Determine the Dose-Response Characteristics of Inhaled Dry Powder GR33343G 12.5mcg, 25mcg, 50mcg, and 100mcg in Patients With Asthma: A Comparison With Inhaled Salbutamol 200mcg
SLGH08 Completed A Single-Centre, Single-Dose, Double-Blind, Cross-Over Study to Compare the Bronchodilator Effects of 50mcg GR33343G Metered-Dose Inhaler and 50mcg GR33343G Dry Powder in Asthmatic Patients
SLGH10 Completed A Double-Blind Cross-Over Study to Determine if 50mcg Inhaled GR33343G (salmeterol) Twice Daily Compared With Salbutamol for 13 Days Caused Tachyphylaxis in Patients With Stable Asthma
SLGH11 Completed A Single-Centre, Randomised, Double-Blind, Cross-Over Study to Compare the Efficacy of Metered-Dose Inhaler and Dry Powder Formulations of GR33343G With That of Salbutamol Inhaler and Placebo in Patients With Asthma
SLGH12 Completed A Single-Dose, Double-Blind, Cross-Over Study to Determine the Efficacy and Duration of Action of Inhaled GR33343G 50mcg, as Metered-Dose Inhaler or Dry Powder, Against Histamine-Induced Bronchoconstriction
SLGH13 Completed To Compare the Effects of Salmeterol and Salbutamol on Speed of Recovery From Methacholine-Induced Bronchoconstriction in Patients With Reversible Airways Disease
SLGH14 Completed To Determine the Duration of Action of Inhaled GR33343G (salmeterol) (50mcg and 100mcg) Against Methacholine-Induced Bronchoconstriction in Patients With Mild to Moderate Reversible Airways Obstruction
SLGH15 Completed A Single-Dose, Double-Blind, Placebo-Controlled, Randomised, Cross-Over Study to Determine the Effect of Salmeterol (50mcg via Metered-Dose Inhaler) on Immediate- and Late-Phase Allergen-Induced Bronchoconstriction and Bronchial Hyper-Responsiveness
SLGH17 Completed A Single-Centre, Double-Blind, Randomised, Cross-Over Study to Determine the Duration of Action of Salmeterol Administered From a Metered-Dose Inhaler Against Exercise-Induced Bronchospasm in Patients With Asthma
SLGH18 Completed A Cumulative Dosing, Double-Blind, Double-Dummy, Cross-Over Study to Compare the Efficacy of 175mcg GR33343G Administered by 4-Place Diskhaler With 175mcg GR33343G Administered by 8-Place Diskhaler in Asthmatic Patients
SLGH30 Completed A Study to Determine the Duration of Action of Inhaled Salmeterol During Exercise Challenge Tests in Asthmatic Children
SLGH42 Completed A Study to Determine the Effects of Chronic Dosing With Inhaled Salmeterol on Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease
SLGL17 Completed A Single Centre, Randomised, Double-Blind, Cross-Over Study to Compare the Efficacy of Inhaled Salmeterol Xinafoate Dry Powder 50mg BID via the Diskhaler with Placebo Dry Powder BID via the Diskhaler in the Treatment of Non-Reversible COPD Patients and to Provoke with Histamine and…
SLGL24 Completed A double-blind, randomised, parallel group study to investigate the efficacy of inhaled salmeterol 50?g administered twice daily compared with salbutamol 200?g administered four times daily in patients with poorly controlled nocturnal asthma.
SLGL82 Completed A double-blind parallel group study of inhaled salmeterol in asthmatic patients

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.